Germinal center B-cell like diffuse large B-cell lymphoma

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study in Patients with Relapsed/Refractory B-cell Malignancies

Retrieved on: 
Tuesday, June 20, 2023
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, CLL, Follicular lymphoma, Lymphocytosis, SLL, Mantle cell lymphoma, DLBCL, Clinical trial, Pharmacokinetics, Intelligence, Chimera, BTK, Drug resistance, Germinal center B-cell like diffuse large B-cell lymphoma, Patient, Drug discovery, MCL, Chronic lymphocytic leukemia, Safety, Pharmaceutical industry

Accutar Biotechnology, Inc ., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.

Key Points: 
  • Accutar Biotechnology, Inc ., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today announced the dosing of the first patient in a Phase 1 study of AC0676, an orally bioavailable, chimeric degrader molecule designed to target and degrade Bruton's Tyrosine Kinase (BTK) with high potency, selectivity, and broad mutant coverage.
  • "The initiation of this study distinguishes Accutar as the first company to successfully bring oral chimeric degraders against three different targets into the clinic," said Jie Fan, Ph.D., Chief Executive Officer of Accutar Biotechnology, Inc. "Leveraging our protein crystallography and AI-empowered PPI-TAC (Protein-Protein Interaction Targeting Chimera) platforms, AC0676 was designed to potently and selectively degrade both wildtype BTK and BTK mutations that confer drug resistance to both covalent and non-covalent BTK inhibitors, including but not limited to C481S and kinase dead mutations such as L528W.
  • We are excited about the differentiated therapeutic profile of AC0676 and its broad potential to treat patients with B-cell malignancies.”
    The purpose of the Phase 1 multi-center, open-label study is to assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of AC0676 treatment in patients with relapsed/refractory B-cell malignancies, including Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), non-GCB Diffuse Large B-cell Lymphoma (DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL), , Marginal Zone Lymphoma (MZL), or Waldenström Macroglobulinemia (WM).
  • Additional information on this clinical trial can be found on www.clinicaltrials.gov (NCT05780034).

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 24, 2023
SDMA, MTAP, Incentive program, WSE, Patient, PIM, MM, EIB, Leukemia, Therapy, Warsaw Stock Exchange, Service, MTA, Culture, DLBCL, Multiple myeloma, Research, WT, Hematology, Growth, European Investment Bank, Phase, Common, BioNTech, WIG20, AACR, BofA Securities, Cancer, IC50, 100 Best Companies to Work For, Acute myeloid leukemia, American Association for Cancer Research, Publication, Germinal center B-cell like diffuse large B-cell lymphoma, SWIG, HL, Update, PRMT5, Partnership, Exelixis, AML, Pharmaceutical industry, Vaccine, Medical imaging

“2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.

Key Points: 
  • “2022 was a highly productive year for Ryvu as we made significant strides across our clinical programs, collaboration activity, and in strengthening our balance sheet,” said Pawel Przewiezlikowski, co-founder, largest shareholder and CEO of Ryvu Therapeutics.
  • Among the investors participating in this offering were also company insiders (including the CEO) with a total investment of over $5M in the offering.
  • Cash Position – On December 31, 2022, Ryvu Therapeutics held $23.2M in cash and cash equivalents, compared to $20.5M at the end of 2021.
  • Net Loss Attributable to Common Shareholders – Net loss attributable to common shareholders excluding the non-cash cost of valuation of the Incentive Program was $1.4M, for the fourth quarter of 2022, compared to the $2.6M, for the fourth quarter of 2021.

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
IND, Radiopharmaceutical, Oncology, National Cancer Institute, Health, University, Lymphoma, Eli Lilly, Therapy, Merck Group, Merck, Germinal center B-cell like diffuse large B-cell lymphoma, Science, Master of Science, University Hospital Heidelberg, CD38, Organic chemistry, IPO, MD, FDA, Head, Chinese Academy of Sciences, NBE, Novo Nordisk, Boehringer Ingelheim, CSO, CD19, EGFR, RDC, Cancer, Full Life Christian Centre, Clinical trial, German Cancer Research Center, CMO, Acquisition, Doctor of Philosophy, Anti-CD19 immunotoxin, S.A, PSMA, Pharmaceutical industry, Lilly, Chemistry

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Key Points: 
  • MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 16, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
  • Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
  • "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
  • Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.

Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer

Retrieved on: 
Tuesday, January 17, 2023
IND, Radiopharmaceutical, Oncology, National Cancer Institute, Health, University, Lymphoma, Eli Lilly, Therapy, Merck Group, Merck, Germinal center B-cell like diffuse large B-cell lymphoma, Science, Master of Science, University Hospital Heidelberg, CD38, Organic chemistry, IPO, MD, FDA, Head, Chinese Academy of Sciences, NBE, Novo Nordisk, Boehringer Ingelheim, CSO, CD19, EGFR, RDC, Cancer, Full Life Christian Centre, Clinical trial, German Cancer Research Center, CMO, Acquisition, Doctor of Philosophy, Anti-CD19 immunotoxin, S.A, PSMA, Pharmaceutical industry, Lilly, Chemistry

MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Key Points: 
  • MANNHEIM, Germany, WATCHUNG, N.J. and SHANGHAI, Jan. 17, 2023 /PRNewswire/ -- Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).
  • Dr. Heeger has held senior oncology clinical development positions at both large and emerging companies for more than 15 years.
  • "He joins Full-Life as we are accelerating plans for our first targeted radiopharmaceuticals to enter clinical trials.
  • Dr. Liu has had a highly successful, 18-year career in therapeutic discovery, including at Eli Lilly and Novo Nordisk.

Ryvu Therapeutics Announces Multiple Presentations of Clinical and Translational Data of RVU120 and SEL24 (MEN1703) at the 2022 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Thursday, November 3, 2022
Lymphatic system, Washington University in St. Louis, Society, DLBCL, Washington University School of Medicine, Knowledge, B-cell lymphoma, Hodgkin lymphoma, Macrophage, Multiple myeloma, Warsaw Stock Exchange, Growth, Merck, GLOBE, FLT3, ASH, RVU, Germinal center B-cell like diffuse large B-cell lymphoma, Publication, Phenotype, Safety, MDS, Drug resistance, Gene expression, Pharmacology, Transfusion medicine, Exposition, Plasma, MM, Institute, PIM, Carcinogenesis, Acute myeloid leukemia, Therapy, Myelodysplastic syndrome, Transplant, AML, Cognition and Neuroergonomics (CaN) Collaborative Technology Alliance, Cellular, Pharmaceutical industry, Medicinal plants, Patient, Hematology, MD

As of the cut-off date of July 25, 2022, 17 patients have been treated with RVU120.

Key Points: 
  • As of the cut-off date of July 25, 2022, 17 patients have been treated with RVU120.
  • Additionally, the on-target activity of RVU120 was evaluated in AML and HR-MDS patient samples by measuring changes in pSTAT5 levels.
  • Ryvu licensee, Menarini Group, and academic collaborators will present data on SEL24(MEN1703), a first-in-class, oral, dual type I PIM/FLT3 inhibitor.
  • We are also proud that our partner Menarini will showcase multiple preclinical data on SEL24 showing potential efficacy across multiple blood cancer models.

AKSO Announces Publication of Preclinical Data Demonstrating Engineered Soluble BCMA Decoy Receptor AB001 Effectively Inhibits Multiple Myeloma and Diffuse Large B Cell Lymphoma

Retrieved on: 
Wednesday, July 27, 2022
Research, Infectious Diseases, Hospitals, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, BAFF, View, TACI, APRIL, Journal, Degenerative disease, Genetic disorder, DLBCL, Cancer, DEEP, Multiple myeloma, Medical research, Patient, Survival, BCMA, Therapy, Germinal center B-cell like diffuse large B-cell lymphoma, Mouse, Autoimmune disease, Growth, BAFF receptor, Vaccine, Pharmaceutical industry

AKSO Biopharmaceutical, Inc. (AKSO), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune disease, and genetic disorder, announced the publication in the Journal of Experimental Medicine of preclinical data demonstrating that AKSOs late preclinical stage molecule AB001 effectively inhibits growth of Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL) in mice.

Key Points: 
  • AKSO Biopharmaceutical, Inc. (AKSO), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune disease, and genetic disorder, announced the publication in the Journal of Experimental Medicine of preclinical data demonstrating that AKSOs late preclinical stage molecule AB001 effectively inhibits growth of Multiple Myeloma (MM) and Diffuse Large B Cell Lymphoma (DLBCL) in mice.
  • Collectively, our data support AB001 as a clinically viable candidate for the treatment of MM and DLBCL.
  • AB001 is a late preclinical stage first-in-class and best-in-class engineered soluble BCMA decoy receptor.
  • AB001 traps APRIL and BAFF with ultra-high binding affinities thereby inhibiting ligand mediated activation of receptors BCMA, BAFF Receptor and TACI.

IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility

Retrieved on: 
Wednesday, June 22, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toronto Stock Exchange, CD8, IMV, TSX, Mission statement, Technology, Person, Government, Compliance, SEDAR, CD4, Company, DLBCL, Forward-looking statement, LinkedIn, Germinal center B-cell like diffuse large B-cell lymphoma, CAD, Immune system, Securities Act of 1933, Immunotherapy, Regulation, NASDAQ, Share (finance), Ovarian cancer, Nasdaq, Survivin, Twitter, DPX, Terminology, Hematological Cancer Research Investment and Education Act, EDGAR, Bladder cancer, Income, Sale, Pharmaceutical industry, Security (finance)

Horizon is pleased to continue supporting IMV as the company makes important progress with the AVALON trial, said Gerald A. Michaud, President of Horizon.

Key Points: 
  • Horizon is pleased to continue supporting IMV as the company makes important progress with the AVALON trial, said Gerald A. Michaud, President of Horizon.
  • We believe in IMVs mission of building a new class of effective cancer immunotherapies that preserve patients quality of life.
  • US$15 million of the US$25 million facility was already drawn down in December 2021, of which CAD$4.5 million was used to pay off IMVs existing term loan with the government of Nova Scotia.
  • IMV Inc. assumes no responsibility to update forward-looking statements in this press release except as required by law.

Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Wednesday, April 13, 2022
Protein, Immunity, CD25, Germinal center B-cell like diffuse large B-cell lymphoma, DNA, IL-2, COVID-19, Association, Lymphatic system, Risk, NASDAQ, University, CD8, Toxicity, Bias, Immunotherapy, Private Securities Litigation Reform Act, Syngenic, GLOBE, Department, Patient, Cell, Inflammation, Trial of the century, Breast, Technology, Autoimmunity, ADCC, Hematological Cancer Research Investment and Education Act, Radiation, SEC, MD Anderson Cancer Center, Forward-looking statement, American Association for Cancer Research, Safety, NK, De novo, RT, American Association, Brain, AACR, Therapy, Cancer, Survival, Vaccine, Pharmaceutical industry, Medical imaging, Medical device

SEATTLE, April 13, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data and a trial in progress overview for its immunotherapy candidate NL-201, an IL-2 and IL-15 agonist, at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • The research presented by Neoleukin researchers highlights the potential for NL-201 to treat hematologic cancers.
  • We believe these data support the potential for NL-201 to provide broad benefit across a range of indications and in combination with other modalities of therapy to improve outcomes for cancer patients.
  • Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology.
  • Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.

Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Oncology, Health, Other Health, Other Science, Research, Science, Biotechnology, Treatment, Company, Therapy, Germinal center B-cell like diffuse large B-cell lymphoma, Chromatin, Poster, IC50, B-cell lymphoma, Growth, Adult, ADME, AACR, American Association, Ernest, Probability, ABC, Cancer, CEO, Association, American Association for Cancer Research, PMBL, Science, GCB, Patient, Pharmaceutical industry, Medical imaging, Vaccine, DLBCL

Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Companys first-in-class KDM4 inhibitor, at the American Association for Cancer Research ("AACR") Annual Meeting 2022.

Key Points: 
  • Tachyon Therapeutics, Inc. ("Tachyon" or "the Company"), a private biotechnology company developing transformative cancer therapies against novel targets, today shared preclinical data for TACH101, the Companys first-in-class KDM4 inhibitor, at the American Association for Cancer Research ("AACR") Annual Meeting 2022.
  • TACH101 is an investigational agent for the potential treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).
  • These preclinical data on TACH101 highlight its anti-tumor activity in DLBCL, the most common and aggressive type of non-Hodgkin lymphoma, said Frank Perabo, M.D., Ph.D., CEO of Tachyon Therapuetics.
  • AACR 2022 is taking place both virtually and in-person at the Ernest N. Morial Convention Center in New Orleans from April 8-13, 2022.

Bantam Pharmaceutical and Collaborators to Present New Data in Support of its lead drug BTM-3566 at AACR Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022
PDX, Germinal center B-cell like diffuse large B-cell lymphoma, Therapy, Cell death, Investigational New Drug, PARK, IND, AACR, Cancer, CEO, Neoplasm, Apoptosis, Lymphoid leukemia, Oncology, RESEARCH, Drug discovery, Patient, Pharmaceutical industry, DLBCL

Emerging data characterizing the responses and dependency on expression of a mitochondrial protein will also be presented.

Key Points: 
  • Emerging data characterizing the responses and dependency on expression of a mitochondrial protein will also be presented.
  • Michael Stocum, CEO of Bantam Pharmaceutical, commented: "We are excited to be presenting this new data at AACR.
  • We expect to file an Investigational New Drug (IND) application for BTM-3566 this quarter (2Q 2022) and are prepared to initiate clinical trials later this year.
  • Bantam Pharmaceutical is a drug discovery and development company channelingthe power of mitochondrial dynamics to address unmet needs in oncology.